Eisai Co., Ltd.
Research Eisai Co., Ltd. (4523.T) on Bullrun: market cap JPY 1.39T, P/E 36.0, dividend yield 3.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4523.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyJPY
- Market capJPY 1.39T
- P/E36.0
- Dividend yield3.2%
- Financial periodFY2026
- RevenueJPY 825.38B
- Revenue growth4.6%
- Net incomeJPY 38.56B
- Free cash flowJPY 20.16B
- Gross margin76.8%
Valuation Snapshot
latest market cap is JPY 1.39T; P/E is 36.0; dividend yield is 3.2%.
Peer valuation comparison
Latest P/E is 35.97x versus a Healthcare sector median of 21.69x (65.8% above).
Latest dividend yield is 3.21% versus a Healthcare sector median of 2.41% (33.2% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 825.38B | JPY 38.56B | JPY 20.16B | 76.8% | 136.78 | JPY 245.42B | JPY 186.08B | JPY 898.99B |
| FY2025 | JPY 789.40B | JPY 46.43B | JPY 7.15B | 78.6% | 163.76 | JPY 265.56B | JPY 187.52B | JPY 841.42B |
| FY2024 | JPY 741.75B | JPY 42.41B | JPY 31.17B | 79.1% | 147.86 | JPY 304.68B | JPY 159.41B | JPY 875.61B |
| FY2023 | JPY 744.40B | JPY 55.43B | -JPY 36.33B | 76.1% | 193.31 | JPY 267.35B | JPY 126.11B | JPY 799.96B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 1.39T | 36.0 | 3.3% | 160 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 160 JPY, yield 3.2%.
| Year | Dividends/share |
|---|---|
| FY2026 | 160 JPY |
| FY2025 | 160 JPY |
| FY2024 | 160 JPY |
| FY2023 | 160 JPY |
About Eisai Co., Ltd.
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs;
ETFs that hold Eisai Co., Ltd.
Eisai Co., Ltd. is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| iShares Ageing Population UCITS ETF USD (Acc) | 0.65% | 0.40% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Eisai Co., Ltd.'s market cap?
Eisai Co., Ltd.'s market capitalization is JPY 1.39T.
What is Eisai Co., Ltd.'s P/E ratio?
Eisai Co., Ltd.'s price-to-earnings (P/E) ratio is 36.0.
Does Eisai Co., Ltd. pay a dividend?
Eisai Co., Ltd. has a dividend yield of 3.2%.
What does Eisai Co., Ltd. do?
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas.